EDMONTON, ALBERTA, CANADA - New discoveries at the University of Alberta overseen by Evangelos Michelakis suggest a milestone in the cure for cancer in the form of a drug called dichloroacetate - or DCA for short - that
targets cancerous cells' safeguard against self-destruction.
All normal cells are designed to die when no longer performing properly; their mitochondria activate a process called apoptosis that kills them off. Cancerous cells inhibit the mitochondria that kick off apoptosis, leading to cells upon cells that refuse to die - and thus cancer. DCA is designed to reactivate the dormant mitochondria and force the cancerous cells to consume themselves.
This is a basic fact of cancer and not unique to the breast, throat, lungs-which means that, if DCA indeed holds a cure, it would be a cure for all cancers. Perhaps more amazingly, a DCA cure would be not only universal, but inexpensive; dichloroacetate is neither costly nor difficult to manufacture. Indeed, it is already used in several existing medicines for diseases as diverse as lactic acidosis
No trials have yet been undertaken in human patients, only in human cells outside the body-and the laboratory mainstay, rats-but officials remain hopeful. It may require public funding, as pharmaceutical companies are unlikely to fund research that they cannot control and exclusively sell. DCA is unpatented and thus unprofitable. This issue has plagued cancer research before; one need only think back to developments in the use of Vitamin C to overwhelm cancer cells, not particularly well-funded by the corporate entities that wield the power in the health care world. The University of Alberta has already started an appeal to charities and individual investors through both traditional media and the Web.
All normal cells are designed to die when no longer performing properly; their mitochondria activate a process called apoptosis that kills them off. Cancerous cells inhibit the mitochondria that kick off apoptosis, leading to cells upon cells that refuse to die - and thus cancer. DCA is designed to reactivate the dormant mitochondria and force the cancerous cells to consume themselves.
This is a basic fact of cancer and not unique to the breast, throat, lungs-which means that, if DCA indeed holds a cure, it would be a cure for all cancers. Perhaps more amazingly, a DCA cure would be not only universal, but inexpensive; dichloroacetate is neither costly nor difficult to manufacture. Indeed, it is already used in several existing medicines for diseases as diverse as lactic acidosis
No trials have yet been undertaken in human patients, only in human cells outside the body-and the laboratory mainstay, rats-but officials remain hopeful. It may require public funding, as pharmaceutical companies are unlikely to fund research that they cannot control and exclusively sell. DCA is unpatented and thus unprofitable. This issue has plagued cancer research before; one need only think back to developments in the use of Vitamin C to overwhelm cancer cells, not particularly well-funded by the corporate entities that wield the power in the health care world. The University of Alberta has already started an appeal to charities and individual investors through both traditional media and the Web.
Fibromyalgia: An Overview of Symptoms and Treatment Options
Because fibromyalgia is considered a disorder of both physical and psychological components, ensuring a combination treatment program will ensure the optimal benefits to perform activities of daily living.
Azilect, a Synopsis of Parkinson's Disease Treatment Option
With more than four million people worldwide diagnosed with Parkinson's Disease, Azilect has become a medication utilized to slow the progression of the disease and may prove effective in treatment dementias such as A...
Product Review: Ojon Restorative Hair Treatment
This product review describes a bad experience with the overhyped Ojon Hair Treatment, which supposedly contains a rare oil that fortifies and silkens damaged hair. The product...
Pompe Disease and Treatment
Pompe disease is a rare hereditary genetic deficiency in an enzyme acid, needed to break glycogen, a stored sugar used for energy. The disease develops in various age groups & symptoms. In 2006, FDA approved Myozyme t...
(Guest)
(Guest)
(Guest)
(Guest)
(Guest)
(Guest)
(Guest)
(Guest)
(Guest)
(Guest)